SEC Form 4 · accession 0001209191-18-047750
Evoke Pharma Inc · EVOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Patrick F Latterell
10% Owner
LVP LIFE SCIENCE VENTURES III L.P.
10% Owner
LVP III Associates, L.P.
10% Owner
LVP III Partners LP
10% Owner
LVP GP III, LLC
10% Owner
LVPMC, LLC
10% Owner
Period of report
Aug 20, 2018
Accepted (ET)
Aug 21, 2018 · 4:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001403708
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 20, 2018 | P | 465,116 | $2.35 | A | 1,937,983 | I | Directly owned by LVP III |
| Common StockF1 | Aug 20, 2018 | P | 23,256 | $2.35 | A | 96,897 | I | Directly owned by Associates |
| Common StockF1 | Aug 20, 2018 | P | 11,628 | $2.35 | A | 48,449 | I | Directly owned by Partners |
| Common StockF1 | holding | — | — | — | 5,250 | I | Directly owned by LVPMC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported securities are owned directly by each of LVPMC, LLC ("LVPMC"), LVP Life Science Ventures III, L.P. ("LVP III"), LVP III Associates, L.P. ("Associates") and LVP III Partners, L.P. ("Partners"). LVP GP III, LLC ("GP III") is the general partner of LVP III, Associates and Partners. GP III may be deemed to have sole voting power and dispositive power over the shares held by LVP III, Associates and Partners. Each of GP III and Patrick Latterell, the managing member of GP III and the manager of LVPMC, may be deemed to share voting and dispositive power over the reported securities and disclaim beneficial ownership of the reported securities held by LVPMC, LVP III, Associates and Partners except to the extent of any pecuniary interest therein.